202 related articles for article (PubMed ID: 2892002)
1. The pathogenesis of humoral hypercalcaemia of malignancy.
Ralston SH
Lancet; 1987 Dec; 2(8573):1443-6. PubMed ID: 2892002
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of hypercalcaemia of malignancy.
Mundy GR
Clin Endocrinol (Oxf); 1985 Dec; 23(6):705-14. PubMed ID: 3006948
[TBL] [Abstract][Full Text] [Related]
3. Failure of parathyroid hormone antagonists to inhibit in vitro bone resorbing activity produced by two animal models of the humoral hypercalcemia of malignancy.
D'Souza SM; Ibbotson KJ; Mundy GR
J Clin Invest; 1984 Sep; 74(3):1104-7. PubMed ID: 6470137
[TBL] [Abstract][Full Text] [Related]
4. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.
Horwitz MJ; Tedesco MB; Sereika SM; Hollis BW; Garcia-Ocaña A; Stewart AF
J Clin Endocrinol Metab; 2003 Apr; 88(4):1603-9. PubMed ID: 12679445
[TBL] [Abstract][Full Text] [Related]
5. Tumors of the parathyroid gland and circulating parathyroid hormone-related protein associated with persistent hypercalcemia.
Rosol TJ; Capen CC
Toxicol Pathol; 1989; 17(2):346-56. PubMed ID: 2675285
[TBL] [Abstract][Full Text] [Related]
6. Hyperparathyroidism, humoral hypercalcemia of malignancy, and the anabolic actions of parathyroid hormone and parathyroid hormone-related protein on the skeleton.
Stewart AF
J Bone Miner Res; 2002 May; 17(5):758-62. PubMed ID: 12009005
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans.
Everhart-Caye M; Inzucchi SE; Guinness-Henry J; Mitnick MA; Stewart AF
J Clin Endocrinol Metab; 1996 Jan; 81(1):199-208. PubMed ID: 8550752
[TBL] [Abstract][Full Text] [Related]
8. Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy.
Stewart AF; Insogna KL; Goltzman D; Broadus AE
Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1454-8. PubMed ID: 6298791
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone-related protein and hypercalcemia.
Rankin W; Grill V; Martin TJ
Cancer; 1997 Oct; 80(8 Suppl):1564-71. PubMed ID: 9362423
[TBL] [Abstract][Full Text] [Related]
10. Malignancy-associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome.
Schweitzer DH; Hamdy NA; Frölich M; Zwinderman AH; Papapoulos SE
Clin Endocrinol (Oxf); 1994 Aug; 41(2):251-6. PubMed ID: 7923831
[TBL] [Abstract][Full Text] [Related]
11. Two species of adenylate cyclase-stimulating activity in a murine squamous carcinoma model of humoral hypercalcemia of malignancy.
Burtis WJ; Broadus AE; Insogna KL; Weir EC; Stewart AF
Endocrinology; 1986 May; 118(5):1982-8. PubMed ID: 3009144
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone-related protein: a novel gene product.
Martin TJ; Suva LJ
Baillieres Clin Endocrinol Metab; 1988 Nov; 2(4):1003-29. PubMed ID: 3077245
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of humoral hypercalcemia of malignancy.
Rosol TJ; Capen CC
Domest Anim Endocrinol; 1988 Jan; 5(1):1-21. PubMed ID: 3066580
[TBL] [Abstract][Full Text] [Related]
14. Hypercalcemia of malignancy: pathophysiology, diagnosis and treatment.
Mosekilde L; Eriksen EF; Charles P
Crit Rev Oncol Hematol; 1991; 11(1):1-27. PubMed ID: 1883526
[TBL] [Abstract][Full Text] [Related]
15. Bone resorption and humoral hypercalcemia of malignancy: stimulation of bone resorption in vitro by tumor extracts is inhibited by prostaglandin synthesis inhibitors.
Minkin C; Fredericks RS; Pokress S; Rude RK; Sharp CF; Tong M; Singer FR
J Clin Endocrinol Metab; 1981 Nov; 53(5):941-7. PubMed ID: 6793615
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone-related protein and calcium phosphate metabolism.
Law F; Ferrari S; Rizzoli R; Bonjour JP
Pediatr Nephrol; 1993 Dec; 7(6):827-33. PubMed ID: 8130117
[TBL] [Abstract][Full Text] [Related]
17. Humoral hypercalcemia of malignancy. The role of parathyroid hormone-related protein.
Insogna KL
Endocrinol Metab Clin North Am; 1989 Sep; 18(3):779-94. PubMed ID: 2673773
[TBL] [Abstract][Full Text] [Related]
18. Co-purification of transforming growth factor beta-like activity with PTH-like and bone-resorbing activities from a tumor associated with humoral hypercalcemia of malignancy.
Insogna KL; Weir EC; Wu TL; Stewart AF; Broadus AE; Burtis WJ; Centrella M
Endocrinology; 1987 May; 120(5):2183-5. PubMed ID: 3494596
[TBL] [Abstract][Full Text] [Related]
19. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
[TBL] [Abstract][Full Text] [Related]
20. Contrasting mechanisms of hypercalcemia in patients with early and advanced humoral hypercalcemia of malignancy.
Ralston SH; Boyce BF; Cowan RA; Gardner MD; Fraser WD; Boyle IT
J Bone Miner Res; 1989 Feb; 4(1):103-11. PubMed ID: 2718773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
